Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 30;18(7):2156753.
doi: 10.1080/21645515.2022.2156753. Epub 2022 Dec 28.

Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six months

Rima R Sahay  1 , Pragya D Yadav  1 , Ashok Nandapurkar  2 , Rutuja Dhawde  1 , Annasaheb Suryawanshi  1 , Deepak Y Patil  1 , Anita M Shete  1 , Gajanan N Sapkal  1 , Milind Kulkarni  2 , Yogesh K Gurav  1 , Gururaj R Deshpande  1 , Jagdevi S Ghodke  2 , Rajlaxmi Jain  1 , Raj Hawale  1 , Kaumudi Kalele  1 , Jyoti Yemul  1 , Pranita Gawande  1 , Priya Abraham  1
Affiliations

Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six months

Rima R Sahay et al. Hum Vaccin Immunother. .

Abstract

We have evaluated the immunogenicity of two dose of Covaxin given at a one-month interval to two adult populations, i.e. COVID-19 naïve-vaccinated individuals (n = 118) and COVID-19 recovered individuals (n = 128) with the vaccination. The immune response in the study population were assessed at three follow-ups, namely at one month post first dose, one and six months after the second dose. The persistence of S1RBD IgG and neutralizing antibodies for six months post vaccination was observed at different time intervals. The enhanced immune response was observed in both the participant groups. The study emphasizes the need for a booster dose post six months of vaccination.

Keywords: Covaxin; Sars-CoV-2; adult population; immunogenicity.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the authors.

Figures

Figure 1.
Figure 1.
Cohort of adults immunized with Covaxin (BBV152) in Pune, India and their follow up during June 2021 – March 2022.
Figure 2.
Figure 2.
The S1-RBD IgG antibody titer of the sera of study subjects at one month post first dose, 1 month post second dose, and 6 months post second dose from a) Group 1 (COVID-19 naïve individuals) and b) Group 2 (COVID-19 recovered individuals) vaccinated with two doses of Covaxin. The neutralizing antibody titer of sera of study subjects at second dose, 1 month post second dose, and 6 months post second dose from c) Group 1 and d) Group 2 against SARS-CoV-2 B.1, Delta, Omicron BA.1 and BA.2 variants. Differences across time points, categories, ELISA and SARS-CoV-2 variants were analyzed using paired t-tests; p-value less than 0.05 were considered to be statistically significant. The dotted line on the figures indicates the limit of detection of the assays. The data is presented as mean value ± standard deviation. All the analyses were performed using GraphPad PRISM version 9.0.
See this image and copyright information in PMC

References

    1. Fisayo T, Tsukagoshi S.. Three waves of the COVID-19 pandemic. Postgrad Med J. 2021. May 1;97(1147):332. doi:10.1136/postgradmedj-2020-138564. - DOI - PMC - PubMed
    1. Bogam P, Joshi A, Nagarkar S, Jain D, Gupte N, Shashidhara LS, Monteiro JM, Mave V. Burden of COVID-19 and case fatality rate in Pune, India: an analysis of the first and second wave of the pandemic. IJID Regions. 2022;2:74–4. doi:10.1016/j.ijregi.2021.12.006. - DOI - PMC - PubMed
    1. Nagy A, Alhatlani B. An overview of current COVID-19 vaccine platforms. Comput Struct Biotechnol J. 2021;19:2508–17. doi:10.1016/j.csbj.2021.04.061. - DOI - PMC - PubMed
    1. Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, Ganneru B, Sapkal G, Yadav P, Abraham P, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021;21(5):637–46. doi:10.1016/S1473-3099(20)30942-7. - DOI - PMC - PubMed
    1. World Health Organization . Annexes to the interim recommendations for use of the bharat biotech BBV152 COVAXIN® vaccine against COVID-19. [accessed 2022 Sep15]. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-reco....

Publication types